Consensus on the Clinical Use of Pregabalin in Peripheral Neuropathic Pain
Open Access
- 17 June 2026
- journal article
- review article
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (6) , e70866
Abstract
Background: Peripheral neuropathic pain (pNP) is a prevalent and complex clinical condition that presents significant therapeutic challenges, with pharmacological options demonstrating variable efficacy and safety. Objective: To establish expert consensus recommendations on the clinical use of pregabalin in the management of diverse pNP conditions. Methods: A multidisciplinary panel of Chinese experts from orthopedics, pain management, neurology, oncology, dermatology, and pharmacy conducted a comprehensive literature review and synthesized clinical evidence to formulate consensus‐based recommendations. Results: Pregabalin, a second‐generation calcium channel regulator, demonstrated broad efficacy across multiple pNP conditions, including postherpetic neuralgia (PHN), diabetic peripheral neuropathy (DPN), neuropathic cancer pain (NCP), postoperative and post‐traumatic neuralgia, and trigeminal neuralgia (TN). In PHN, pregabalin significantly reduced pain intensity and improved sleep quality. In DPN, it provided consistent analgesia with improved pain scores and good tolerability. In NCP, pregabalin effectively alleviated pain, showed no significant drug–drug interactions, and was safely co‐administered with chemotherapy. It was also effective in postoperative and post‐traumatic neuralgia, although caution is warranted in cases of traumatic neuroma. In TN, pregabalin exhibited favorable low‐dose efficacy, particularly in elderly patients, with minimal adverse effects. However, cautious use is advised in patients with nerve compression syndromes, such as carpal tunnel syndrome, and in individuals with a history of substance abuse. Conclusions: This consensus highlights pregabalin as an effective and generally well‐tolerated therapeutic option for a broad range of pNP conditions. These recommendations provide clinically relevant guidance for optimizing pregabalin use, particularly within the Chinese healthcare context.Keywords
This publication has 133 references indexed in Scilit:
- Pregabalin Population Pharmacokinetic and Exposure‐Response Analyses for Focal Onset Seizures in Children (4–16 years) and Adults, to Support Dose Recommendations in ChildrenClinical Pharmacology & Therapeutics, 2020
- Association of Gabapentinoids With the Risk of Opioid-Related Adverse Events in Surgical Patients in the United StatesJAMA Network Open, 2020
- Pregabalin in the Management of Painful Diabetic Neuropathy: A Narrative ReviewDiabetes Therapy, 2018
- Transport of Pregabalin Via L-Type Amino Acid Transporter 1 (SLC7A5) in Human Brain Capillary Endothelial Cell LinePharmaceutical Research, 2018
- Staphylococcus aureus protein A enhances osteoclastogenesis via TNFR1 and EGFR signalingBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2016
- Abuse Potential of PregabalinCNS Drugs, 2016
- Peripheral neuropathies2016
- Lamotrigine Versus Pregabalin in the Management of Refractory Trigeminal Neuralgia: A Randomized Open Label Crossover TrialJournal of Maxillofacial and Oral Surgery, 2013
- A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteersPsychopharmacology, 2005
- Paclitaxel Delivered as a 3-hr Infusion with Cisplatin in Patients with Gynecologic Cancers: Unexpected Incidence of NeurotoxicityGynecologic Oncology, 1996